



BASL WINTER MEETING DECEMBER 3RD 2021

LOCATION: WALLONIA CONFERENCE CENTER MONS

AVENUE MÉLINA MERCOURI 7-BE 7000 - MONS

WWW.WCCM.EU

- 08.30-09.00 **Registration**
- 09.00-10.45 **Session 1 : News from Baveno VII** (*moderators : Jean Delwaide - CHU Liège, Hendrik Reynaert - UZ Brussel*)
 - Use of non-invasive tests to guide clinical decision making in cirrhosis and portal hypertension. (Aleksander Krag, Odense University Hospital, Denmark)
 - Treatment of acute variceal bleeding: state of the art. (Juan Carlos García Pagán, Hospital Clinic, Barcelona, Spain)
 - Primary and secondary prophylaxis: new perspectives. (Wim Laleman, UZ Leuven)
- 10.45-11.15 **Coffee Break**
- 11.15-12.45 **Session 2 : NON-INTERACTIVE DISCUSSION OF CLINICAL CASES** (*moderators : M. De Vos - Jolimont, W. Verlinden - AZ Nikolaas*)
 Presentations BASL YOUNG INVESTIGATORS AWARD LAUREATES 2021 and short presentation by 2020 Laureates
- 12.45-13.00 Presentations BASL YOUNG INVESTIGATORS AWARD LAUREATES 2021 and short presentation by 2020 Laureates
- 13.00-13.15 BASL awards and grants 2021
- 13.15-14.00 **LUNCH**
- 14.00-15.45 **Session 3 : Do we still need liver biopsy in Hepatology? Pros and cons in our daily practice: Clinico-pathological discussions.** (*moderators : Anja Geerts UZ Gent, Pierre Deltenre - Clinique St. Luc, Bouge*)
 - Autoimmune hepatitis: X. Verhelst (UZ Gent) vs A. Hoorens (UZ Gent)
 - NAFLD and ALD: P. Stärkel (UCL) vs L. Libbrecht (AZG Kortrijk)
- 15.45-16.45 **Session 4 : HEPATOLOGY UPDATE** (*moderators : Thomas Vanwolleghem - UZA, Sergio Negrín Dastis - GHdC*)
 - DILI: types and phenotypes (Einar S. Björsson - National University Hospital of Iceland, Reykjavík, Iceland)
 - Beyond lactulose: treatment options in HE (S. Montagnese, University of Padova, Italy)
- 17.00 **Conclusion and farewell**

BASL LIVER COURSE HEPATOCELLULAR CARCINOMA DECEMBER 4TH 2021



- 08.30-09.00 **Registration**
- Session 1** *Moderators : E. Trepo (ULB) - S. Van Hees (UZA)*
 09.00-09.30 Epidemiology of HCC in cirrhotic patients and prevention strategy. (P. Jepsen, Aarhus University, Denmark)
 09.30-10.00 New diagnostic and prognostic tools in HCC. (I. Borbath, UCL)
 10.00-10.30 Staging systems and treatment allocation in HCC. (M. Colombo, Ospedale San Raffaele, Milano, Italy)
- 10.30-11.00 **Coffee Break**
- Session 2** *Moderators : B. Delire (UCL) - O. Koc (UHasselt)*
 11.00-11.30 Non surgical treatment of HCC: the role of SIRT, TARE, TACE, MWA. (H. Degroote, UZ Gent)
 11.30-12.00 Systemic treatments in HCC: indications, outcomes and complications. (J. Dekervel, UZ Leuven)
 12.30-13.00 Why transplantation should be considered as the best therapeutic option for HCC. (J. Pirenne, UZ Leuven)
- 12.30 **Conclusion and farewell**

REGISTRATION REQUIRED VIA E-MAIL ONLY : BASL@BASL.BE

access conditions : MEMBERSHIP PAID PRIOR TO CONGRESS + valid COVID SAFE TICKET

abbvie



CSL Behring
Biotherapies for Life™



echosens

sobi